Compare CYD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | AUPH |
|---|---|---|
| Founded | 1951 | 1993 |
| Country | Singapore | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1998 | 2014 |
| Metric | CYD | AUPH |
|---|---|---|
| Price | $49.30 | $16.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $60.00 | $17.25 |
| AVG Volume (30 Days) | 204.9K | ★ 1.1M |
| Earning Date | 02-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $15.11 | $17.54 |
| Revenue Next Year | $8.67 | $15.74 |
| P/E Ratio | ★ $32.71 | $65.72 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $21.10 | $7.29 |
| 52 Week High | $61.48 | $16.88 |
| Indicator | CYD | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 59.45 |
| Support Level | $35.70 | $14.60 |
| Resistance Level | $56.55 | $16.88 |
| Average True Range (ATR) | 3.36 | 0.52 |
| MACD | -1.11 | 0.07 |
| Stochastic Oscillator | 16.79 | 80.92 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.